Dexcom

Historical price data

Dexcom has established itself as the market leader in continuous glucose monitoring technology over 25 years, transforming diabetes care with real-time glucose tracking that eliminates the need for fingerstick testing. The company's flagship Dexcom G7 system represents the most accurate CGM technology available, while their new Stelo biosensor expands their addressable market to people without diabetes seeking metabolic health insights. With a strong commercial presence and robust innovation pipeline, Dexcom continues to set the standard in glucose biosensing technology.

Advanced glucose biosensing technology that enables continuous, real-time monitoring of interstitial glucose levels through wearable sensors integrated with smartphone applications and connected device ecosystems.

4 drugs in pipeline, 2 in Phase 3

Total raised: $500M

Dexcom competes primarily with Abbott's FreeStyle Libre (market leader by volume) and Medtronic's Guardian series, differentiating through superior accuracy and real-time connectivity features. The company maintains technology leadership in the premium CGM segment while expanding into consumer health markets with first-mover advantage.